Effectiveness of Early Antiretroviral Therapy Initiation to Improve Survival among HIV-Infected Adults with Tuberculosis: A Retrospective Cohort Study

PLoS Medicine

Volumn 8, Issue 5, 2011, Pages

  Franke, Molly F ^a,b   Robins, James M ^a   Mugabo, Jules ^c   Kaigamba, Felix ^d   Cain, Lauren E ^a   Fleming, Julia G ^b   Murray, Megan B ^a,e  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b PARTNERS IN HEALTH   (United States)

^c Rwanda Ministry of Health   (Rwanda)

^d Ruhengeri Hospital   (Rwanda)

^e BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; EFAVIRENZ; ETHAMBUTOL; ISONIAZID; LAMIVUDINE; NEVIRAPINE; PYRAZINAMIDE; RIFAMPICIN; STAVUDINE; ZIDOVUDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ADULT; AGED; CD4 LYMPHOCYTE COUNT; COHORT ANALYSIS; CONTROLLED STUDY; DEATH; DISEASE SEVERITY; DRUG EFFICACY; FEMALE; FOLLOW UP; HOSPITALIZATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; OPPORTUNISTIC INFECTION; RETROSPECTIVE STUDY; REVIEW; RWANDA; SIMULATION; SURVIVAL RATE; TREATMENT RESPONSE; TUBERCULOSIS; ADOLESCENT; ARTICLE; MIDDLE AGED; MORTALITY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR; STATISTICAL ANALYSIS; SURVIVAL; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; DATA INTERPRETATION, STATISTICAL; FEMALE; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RETROSPECTIVE STUDIES; RISK FACTORS; RWANDA; SURVIVAL ANALYSIS; TREATMENT OUTCOME; TUBERCULOSIS; YOUNG ADULT;

EID: 79957974326     PISSN: 15491277     EISSN: 15491676     Source Type: Journal    
DOI: 10.1371/journal.pmed.1001029     Document Type: Review

References (32)

1. Burman W, Weis S, Vernon A, Khan A, Benator D, et al. (2007) Frequency, severity and duration of immune reconstitution events in HIV-related tuberculosis. Int J Tuberc Lung Dis 11: 1282-1289.
2. Lawn SD, Myer L, Bekker L, Wood R, (2007) Tuberculosis-associated immune reconstitution disease: incidence, risk factors and impact in an antiretroviral treatment service in South Africa. AIDS 21: 335-341.
3. Navas E, Martín-Dávila P, Moreno L, Pintado V, Casado JL, et al. (2002) Paradoxical reactions of tuberculosis in patients with the acquired immunodeficiency syndrome who are treated with highly active antiretroviral therapy. Arch Intern Med 162: 97-99.
4. Breen RAM, Smith CJ, Bettinson H, Dart S, Bannister B, et al. (2004) Paradoxical reactions during tuberculosis treatment in patients with and without HIV co-infection. Thorax 59: 704-707.
5. Shelburne SA, Visnegarwala F, Darcourt J, Graviss EA, Giordano TP, et al. (2005) Incidence and risk factors for immune reconstitution inflammatory syndrome during highly active antiretroviral therapy. AIDS 19: 399-406.
6. McIlleron H, Meintjes G, Burman WJ, Maartens G, (2007) Complications of antiretroviral therapy in patients with tuberculosis:drug interactions, toxicity, and immune reconstitution inflammatory syndrome. J Infect Dis 196 (Suppl 1): S63-S75.
7. Dean GL, Edwards SG, Ives NJ, Matthews G, Fox EF, et al. (2002) Treatment of tuberculosis in HIV-infected persons in the era of highly active antiretroviral therapy. AIDS 16: 75-83.
8. Akksilp S, Karnkawinpong O, Wattanaamornkiat W, Viriyakitja D, Monkongdee P, et al. (2007) Antiretroviral therapy during tuberculosis treatment and marked reduction in death rate of HIV-infected patients, Thailand. Emerging Infect Dis 13: 1001-1007.
9. Manosuthi W, Chottanapand S, Thongyen S, Chaovavanich A, Sungkanuparph S, (2006) Survival rate and risk factors of mortality among HIV/tuberculosis-coinfected patients with and without antiretroviral therapy. J Acquir Immune Defic Syndr 43: 42-46.
10. Sanguanwongse N, Cain KP, Suriya P, Nateniyom S, Yamada N, et al. (2008) Antiretroviral therapy for HIV-infected tuberculosis patients saves lives but needs to be used more frequently in Thailand. J Acquir Immune Defic Syndr 48: 181-189.
11. Varma JK, Nateniyom S, Akksilp S, Mankatittham W, Sirinak C, et al. (2009) HIV care and treatment factors associated with improved survival during TB treatment in Thailand: an observational study. BMC Infect Dis 9: 42.
12. Velasco M, Castilla V, Sanz J, Gaspar G, Condes E, et al. (2009) Effect of simultaneous use of highly active antiretroviral therapy on survival of HIV patients with tuberculosis. J Acquir Immune Defic Syndr 50: 148-152.
13. World Health Organization (2005) TB/HIV research priorities in resource-limited settings. WHO/HTM/TB/2005.355, WHO/HIV/2005.03. Geneva: World Health Organization. Available: http:///www.who.int/hiv/pub/tb/research/en/index.html. Accessed 23 February 2010.
14. Blanc F, Havlir DV, Onyebujoh PC, Thim S, Goldfeld AE, et al. (2007) Treatment strategies for HIV-infected patients with tuberculosis: ongoing and planned clinical trials. J Infect Dis 196 (Suppl 1): S46-S51.
15. Rothman K, Greenland S, Lash T, (2008) Modern epidemiology, Philadelphia Lippincott Williams & Wilkins 3rd edition.
16. Abdool Karim SS, Kogieleum N, Grobler A, Padayatchi N, Baxter C, et al. (2010) Timing of initiation of antiretroviral drugs during tuberculosis therapy. N Engl J Med 362: 697-706.
17. Blanc FX, Sok T, Laureillard D, Borand L, Rekacewicz C, et al. (2010) The CAMELIA trial: Cambodian early versus late introduction of antiretrovirals [presentation]. XVIII International AIDS Conference; 22 July 2010; Vienna, Austria.
18. Abdool Karim S, Naidoo K, Padayatchi N, Grobler A, Baxter C, et al. (2011) Optimal timing of ART during TB therapy: findings of the SAPiT trial [abstract]. 18th Conference on Retroviruses and Opportunistic Infections; 27 February-2 March 2011; Boston, Massachusetts, United States of America.
19. Havlir D, Ive P, Kendall M, Luetkemeyer A, Swindells S, et al. (2011) International randomized trial of immediate vs early ART in HIV+ patients treated for TB:ACTG 5221 STRIDE study [abstract]. 18th Conference on Retroviruses and Opportunistic Infections; 27 February-2 March 2011; Boston, Massachusetts, United States of America.
20. Perkins MD, Cunningham J, (2007) Facing the crisis:improving the diagnosis of tuberculosis in the HIV era. J Infect Dis 196 (Suppl 1): S15-S27.
21. Centre de Traitement et de Recherche sur le SIDA (2005) Guide pour la prise en charge thérapeutique du HIV/AIDS.
22. Lawn SD, Myer L, Bekker L, Wood R, (2006) CD4 cell count recovery among HIV-infected patients with very advanced immunodeficiency commencing antiretroviral treatment in sub-Saharan Africa. BMC Infect Dis 6: 59.
23. Robins JM, Hernán MA, Brumback B, (2000) Marginal structural models and causal inference in epidemiology. Epidemiology 11: 550-560.
24. Hernán MA, Hernández-Díaz S, Robins JM, (2004) A structural approach to selection bias. Epidemiology 15: 615-625.
25. Govindarajulu US, Spiegelman D, Thurston SW, Ganguli B, Eisen EA, (2007) Comparing smoothing techniques in Cox models for exposure-response relationships. Stat Med 26: 3735-3752.
26. Wasserman L, (2005) All of nonparametric statistics. New York: Springer.
27. Dheda K, Lampe FC, Johnson MA, Lipman MC, (2004) Outcome of HIV-associated tuberculosis in the era of highly active antiretroviral therapy. J Infect Dis 190: 1670-1676.
28. Moore D, Liechty C, Ekwaru P, Were W, Mwima G, et al. (2007) Prevalence, incidence and mortality associated with tuberculosis in HIV-infected patients initiating antiretroviral therapy in rural Uganda. AIDS 21: 713-719.
29. Palmieri F, Pellicelli AM, Girardi E, De Felici AP, De Mori P, et al. (1999) Negative predictors of survival in HIV-infected patients with culture-confirmed pulmonary tuberculosis. Infection 27: 331-334.
30. Manosuthi W, Kiertiburanakul S, Phoorisri T, Sungkanuparph S, (2006) Immune reconstitution inflammatory syndrome of tuberculosis among HIV-infected patients receiving antituberculous and antiretroviral therapy. J Infect 53: 357-363.
31. Pepper DJ, Rebe K, Morroni C, Wilkinson RJ, Meintjes G, (2009) Clinical deterioration during antitubercular treatment at a district hospital in South Africa: the importance of drug resistance and AIDS defining illnesses. PLoS ONE 4: e4520 doi:10.1371/journal.pone.0004520.
32. Castelnuovo B, Manabe YC, Kiragga A, Kamya M, Easterbrook P, et al. (2009) Cause-specific mortality and the contribution of immune reconstitution inflammatory syndrome in the first 3 years after antiretroviral therapy initiation in an urban African cohort. Clin Infect Dis 49: 965-972.